Clinical trials: FAPI PET
Cancer
Clinical Study of Trap (FAPI) 3 PET Imaging in Noninvasive Diagnosis of Malignant Tumors
Positron Emission Tomography (PET) is a functional imaging technology for diagnosing and monitoring tumors. In clinical applications for malignant tumors, PET includes staging, response assessment, and prognosis prediction…
- Trial name
- NCT07128277
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Cancer
The Therapeutic Efficacy of 18F-FDG Combined With 18F-FAPI PET/MR in Neoadjuvant Therapy for Gastric Cancer
Gastric cancer is the fifth most common cancer worldwide and the third leading cause of cancer-related deaths. Although surgical treatment can benefit the survival of the vast majority of patients, currently only early gastric…
- Trial name
- NCT06327386
- Testing
- 18F-FAPI#18F-FDG
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Malignant Tumors, Positron-Emission Tomography
FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application
This clinical trial aims to investigate the value of fibroblast activation protein PET/CT(PET/MR) in the diagnosis, staging, and evaluation of treatment outcomes in malignant tumors.
- Trial name
- NCT06270394
- Testing
- 68Ga-Fibroblast activation protein inhibitor
- Where
- China
- Volunteers
- 22 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Hepatic Malignancies
Role of FAPI PET/MR Combined With Gadoxetate Disodium in Assessing Hepatic Malignancies
This study aimed to prospectively evaluate the utility of fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET)/magnetic resonance (MR) combined with gadoxetate disodium in patients with clinical…
- Trial name
- NCT06287411
- Testing
- FAPI PET/MR combined with gadoxetate disodium
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Xiao Chen
Oral Carcinoma
68Ga-FAPI-04 PET/CT for the Detection of Oral Carcinoma
FAPI is a fibroblast activation protein inhibitor and 68Ga-FAPI-04 is a potential new imaging agent for imaging of carcinoma. 68Ga-FAPI-04 PET/CT is helpful to clarify the benign, malignant and invasive range of the oral…
- Trial name
- NCT05003427
- Testing
- 68Ga-FAPI-04
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Cholangiocarcinoma
The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma
Background Bile duct cancer (cholangiocarcinoma) represents the second most common type of hepatobiliary cancer worldwide with an incidence of 0.35 to 2 per 100.000 annually.
- Trial name
- FAPIChol (NCT06355427)
- Testing
- [18F]F-FAPI PET-CT
- Where
- 3 sites in Netherlands
- Volunteers
- 81 people
- Sponsor
- Mara Veenstra, MD
Hepatocellular Carcinoma, Bile Duct Cancer
FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy
The purpose of this study is to explore the ability of positron emission tomography (PET) with [68Ga]FAPI to detect, evaluate treatment response, and predict prognosis in advanced liver and biliary cancer patients treated with…
- Trial name
- NCT05662488
- Testing
- [68Ga]FAPI PET/CT and [18F]FDG PET/CT
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking Union Medical College Hospital
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to…
- Conditions
- Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury
- Trial name
- NCT07613099
- Testing
- [18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sarcoma
Paediatric Sarcoma, Hybrid Imaging & FAPI - Raising the Diagnostic Standard for Paediatric Sarcoma Patients, Combining Novel Radiotracer FAPI and Whole-body PET/MRI
The goal of this clinical trial is to evaluate [68Ga]FAPI-46 whole-body PET/MRI as a diagnostic tool to improve tumour lesion examination at primary staging, during treatment control and at relapse in paediatric sarcoma patients.
- Trial name
- PsiFI (NCT07861217)
- Testing
- FAPI tracer
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Liver Fibrosis, FAP
18F-FAPI PET in the Diagnosis of Liver Fibrosis
It is an open label observation clinical trial, all participants are chronic liver disease. The investigators deem to make a novel evaluate criteria to hepatic fibrosis.
- Conditions
- Liver Fibrosis, FAP, Positron Emission Tomography
- Trial name
- NCT05262647
- Testing
- 18F-FAPI
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Peritoneal Metastasis, FAPI
The Value of 68Ga-FAPI PET/CT for Evaluating Peritoneal Treatment Response
Peritoneal metastases (PM), commonly originating from gastrointestinal and ovarian cancers, are associated with a poor prognosis and limited treatment options due to the diffuse nature of the disease and the inability of systemic…
- Trial name
- INTERACT-FAPI (NCT06957782)
- Testing
- ⁶⁸Ga-FAPI-46
- Volunteers
- 16 people
- Sponsor
- Erasmus Medical Center
Enhanced CT, 18F-FDG PET/CT
Preoperative Abdominal Enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT in Peritoneal Carcinomatosis of Gastric Cancer
This study aims to explore the value of 68Ga-FAPI PET/CT in the diagnosis of gastric cancer peritoneal carcinomatosis in high-risk patients compared with conventional abdominal enhanced CT and 18F-FDG PET/CT.
- Conditions
- Enhanced CT, 18F-FDG PET/CT, 68Ga-FAPI PET/CT, Gastric Cancer
- Trial name
- NCT04778345
- Testing
- 68Ga-FAPI PET/CT scan
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Fujian Medical University
Prostate Cancer Metastatic Disease, Prostate Cancers
Using FAPI PET/MRI to Evaluate Prostate Cancer
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue.
- Trial name
- NCT06675357
- Testing
- FAPI, Positron Emission Tomography (PET), Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Madison
Lung Cancer
Comparison of 68Ga-FAPI-46 PET and 18F-FDG PET in Lung Cancer
This is a prospective, single-center, single arm, open label study to evaluate the performance of 68Ga-FAPI-46 for the diagnosis of primary and metastatic lesions of lung cancer with comparison to 18F-FDG PET.
- Trial name
- NCT05617742
- Testing
- 68Ga-FAPI-46
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- Chang Gung Memorial Hospital
Urinary Bladder Neoplasms
FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer
The aim of this trial is to investigate the value of FAPI PET/MRI, FDG PET/MRI and MRI in diagnosing MIBC and predicting the efficacy of neoadjuvant therapy for MIBC patients, so as to guide the clinic to adjust the treatment…
- Trial name
- NCT06421142
- Testing
- imaging examinations:FAPI PET/MRI, FDG PET/MRI, MRI
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Lung Nodules
Clinical Study of Trap-(FAPI)3 PET Imaging in the Diagnosis of Pulmonary Nodules
The excellent tumor-targeting efficacy of FAP has been confirmed by multiple clinical studies. The results unequivocally establish FAPI as a tumor-targeting ligand with significant potential, demonstrating important application…
- Trial name
- NCT07448441
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Colorectal Cancer, Peritoneal (Metastatic) Cancer
Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis
Main objective: 1. To compare the objective response rate (ORR) of 18F-FAPI PET-guided abdominal region radiotherapy combined with second-line standard treatment versus cadonilimab and second-line standard treatment in the…
- Conditions
- Colorectal Cancer, Peritoneal (Metastatic) Cancer, FAPI PET
- Trial name
- NCT07079462
- Testing
- Radiotherapy followed by immunotherapy and chemotherapy, Chemotherapy (control)
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Tumor Positron-Emission Tomography
A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study
Both fibroblast activation protein (FAP)-targeted imaging and somatostatin receptors (SSTR)-targeted imaging were the promising imaging modalities for the diagnosis of primary and metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- NCT05990998
- Testing
- 68Ga-DOTATATE and 68Ga-FAPI
- Where
- China
- Volunteers
- 38 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Severe Aortic Valve Stenosis
A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis
This study will include patients with severe degenerative aortic stenosis (AS) who meet the inclusion criteria and voluntarily participate (planned to undergo TAVI), as well as patients with aortic stenosis who have not undergone…
- Trial name
- NCT07335900
- Testing
- Transcatheter Aortic Valve Implantation, Optimal medication treatment
- Where
- China
- Volunteers
- 25 people
- Sponsor
- RenJi Hospital
Oesophageal Cancer, Gastric Cancer
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
The aim of the project is to demonstrate superior detection ratio of [18F]AlF-FAPI-74 PET/CT compared to [18F]FDG PET/CT or conventional imaging in treatment-naïve, newly diagnosed patients with oesophagogastric adenocarcinoma…
- Conditions
- Oesophageal Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma, FAP
- Trial name
- FAPIDO (NCT06782412)
- Testing
- [18F]AlF-FAPI-74 PET/CT
- Where
- 3 sites in Belgium
- Volunteers
- 109 people
- Sponsor
- KU Leuven